GlucoTrack
GCTK
2 hedge funds and large institutions have $163K invested in GlucoTrack in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding
Funds holding: 3 → 2 (-1)
73% less capital invested
Capital invested by funds: $594K → $163K (-$431K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$338K |
| 2 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
-$19.9K |
| 3 |
CHP
Cable Hill Partners
Portland,
Oregon
|
-$8.69K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$7.88K |
GCTK Hedge Fund Activity: Q4 2023 in Review
2 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q4 2023, worth a combined $163K — down 73% from $594K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GCTK and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, cutting an estimated $338K.
- 2 institutional investors held GlucoTrack (GCTK) as of Q4 2023, down from 3 in Q3 2023.
- Funds reported $163K of GlucoTrack stock for Q4 2023, down 73% quarter-over-quarter.
- 0 funds opened new GlucoTrack positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest GlucoTrack seller in Q4 2023 was Sabby Management, an estimated $338K sold.
Based on aggregated 13F filings for Q4 2023.